Clinical Progress
Nventa originally advanced HspE7 as a single-agent therapy into multiple Phase 2 clinical trials with positive results, including trials in cervical dysplasia and recurrent respiratory papillomatosis (RRP). These trials were initiated prior to the discovery that potency could be greatly enhanced by addition of a vaccine adjuvant. Nventa is currently developing HspE7 combined with the TH1-directed adjuvant Poly-ICLC. A Phase 1b study is complete, assessing safety and tolerability in 17 patients with CIN.
Read more about this topic: Nventa Biopharmaceuticals Corporation
Famous quotes containing the word progress:
“An accurate charting of the American woman’s progress through history might look more like a corkscrew tilted slightly to one side, its loops inching closer to the line of freedom with the passage of time—but like a mathematical curve approaching infinity, never touching its goal. . . . Each time, the spiral turns her back just short of the finish line.”
—Susan Faludi (20th century)